CBMG

CBMG Biomedical is a cell therapy company registered in Delaware, USA, listed on the NASDAQ Stock Exchange, with a focus on the Chinese market. The company is primarily engaged in the development of cancer immunotherapies and stem cell therapies for degenerative diseases. CBMG brings together world-class innovative technologies and leading scientists to develop safe treatments for critically ill patients. CBMG brings together world-class innovative technologies and leading scientists to develop safe treatments for critically ill patients.

The company's headquarters is located in Building 3, No. 85 Faraday Road, Zhangjiang, Shanghai, and it has expanded its GMP facility to 70,000 square feet (6,503 square meters) meeting international standards. It has established a strategic partnership with GE China. The company possesses a strong management team, comprehensive clinical research and technical capabilities, and a large number of top medical experts and technical researchers.

Cancer poses a significant threat to global public health and the solvency of health systems. Currently, the treatment needs for these diseases are not fully met. CBMG believes that immune cell therapy is expected to reduce the medical burden caused by these chronic and degenerative diseases in a productive manner. CBMG is developing adult stem cells for regenerative medicine. CBMG has completed a Phase IIb trial in China for Rejoin? autologous adipose-derived mesenchymal progenitor cells (haMPC) for the treatment of knee osteoarthritis (KOA), and a Phase I trial in China for Allojoin? allogeneic human adipose-derived mesenchymal progenitor cells (CBMG's "off-the-shelf" haMPC) for the treatment of KOA.

：*